Results 231 to 240 of about 238,915 (301)

Lipoprotein(a), apolipoprotein B and other lipid biomarkers in Asian healthcare workers. [PDF]

open access: yesLipids Health Dis
Loh WJ   +12 more
europepmc   +1 more source

Frailty and Cardiovascular Events as Determined by Body Composition: A Systematic Review

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Frailty phenotypes and risk of cardiovascular disease. Sarcopenic obese phenotype is associated with increased prevalence of cardiovascular risk factors and progression of metabolic syndrome, leading to cardiovascular events and cardiovascular mortality, while the Anorexic malnourished phenotype is associated with reduced prevalence of cardiovascular ...
Ishleen Oberoi   +5 more
wiley   +1 more source

GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves   +8 more
wiley   +1 more source

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

open access: yesChemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Metabolic profiles of captive Asian elephants (Elephas maximus) in Lao PDR and Thailand. [PDF]

open access: yesPLoS One
López Pérez AB   +7 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy